A three-day course of trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as first-line empirical treatment for acute cystitis in adult women in North America, where resistance of Escherichia coli to TMP-SMX is less than 20% (1,2). TMP-SMX resistance has increased over time (3,4), with a resulting shift toward the use of other antibiotics for acute cystitis, including fluoroquinolones (5,6). There is concern that this may promote the more rapid emergence of fluoroquinoloneresistant uropathogens and reduce the effectiveness of fluoroquinolones in treating more serious infections (7,8).Trying to determine the rate of TMP-SMX resistance in community-acquired cases of acute cystitis has been problematic. Widely varying rates of resistance have been reported in different countries (9) and from different regions within the same country (4). In Canada, a study of outpatients attending tertiary care hospitals found that 19% of E coli isolates were resistant to TMP-SMX; however, the study included men and children (10). Two other community-based studies found that 8% (11) and 11% (12) of E coli isolates were resistant to TMP-SMX. We conducted a national study of community-acquired